A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
|Videos|February 22, 2022
Study into New Possible Treatment of Sturge Weber Syndrome
Author(s)Linda Stocum, Associate Editor
A recent mouse model study on the efficacy of using imatinib as a treatment for Sturge Weber Syndrome has been published. In this video interview we talk with one of the investigators, Jack L. Arbiser, MD, PhD, on what the results means for future clinical trials.
Advertisement
A link to the article is available
Advertisement
Related to this article
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
Advertisement
Advertisement
Trending on Dermatology Times
1
Why Hedgehog Inhibitors Are Not Interchangeable in Locally Advanced BCC
2
AADA Warns of 6% Medicare Payment Cut for Dermatologists in 2027
3
ATTO-1310 Reduces Itch at Week 12 in Chronic Pruritus and Atopic Dermatitis
4
Where Patients With Alopecia Areata Fit on the Path to Systemic Treatment
5